Seegene, Inc.

Equities

A096530

KR7096530001

Biotechnology & Medical Research

End-of-day quote Korea S.E. 06:00:00 2024-04-24 pm EDT 5-day change 1st Jan Change
21,900 KRW -1.35% Intraday chart for Seegene, Inc. +1.86% -4.37%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Seegene, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Seegene Inc. Announces Collaboration with Microsoft to Realize a World Free from All Diseases CI
Microbix and Seegene USA Jointly Enhancing Lab Test Accuracy; Expanded Collaboration Aims To Improve Syndromic Infectious Disease Testing MT
Microbix Brief: Microbix and Seegene USA Jointly Enhancing Lab Test Accuracy MT
Seegene, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Tranche Update on Seegene, Inc.'s Equity Buyback Plan announced on July 13, 2023. CI
Tranche Update on Seegene, Inc.'s Equity Buyback Plan announced on February 28, 2023. CI
Seegene, Inc.'s Equity Buyback announced on February 28, 2023, has expired with 2,046,354 shares, representing 4.11% for KRW 49,998.4 million. CI
Seegene, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Seegene Inc. Unveils Solutions to Popularize Molecular Diagnostics At 2023 AACC CI
Seegene, Inc. announces an Equity Buyback for KRW 30,000 million worth of its shares. CI
Seegene, Inc. authorizes a Buyback Plan. CI
Seegene, Inc. and Werfen Partner to Collaborate on Onesystem Business to Develop Syndromic qPCR Assays CI
Seegene and Werfen Partner to Collaborate on OneSystem(TM) Business to Develop Syndromic qPCR Assays CI
Tranche Update on Seegene, Inc.'s Equity Buyback Plan announced on February 28, 2023. CI
Seegene, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Tranche Update on Seegene, Inc.'s Equity Buyback Plan announced on September 28, 2022. CI
Tranche Update on Seegene, Inc.'s Equity Buyback Plan announced on September 28, 2022. CI
Seegene, Inc.'s Equity Buyback announced on September 28, 2022, has expired with 1,780,608 shares, representing 3.56% for KRW 49,330.84 million. CI
Seegene, Inc. announces an Equity Buyback for KRW 50,000 million worth of its shares. CI
Seegene, Inc. authorizes a Buyback Plan. CI
Tranche Update on Seegene, Inc.'s Equity Buyback Plan announced on September 28, 2022. CI
Seegene, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Seegene, Inc. announces an Equity Buyback for KRW 50,000 million worth of its shares. CI
Seegene, Inc. authorizes a Buyback Plan. CI
Chart Seegene, Inc.
More charts
Seegene Inc is a Korea-based company engaged in the development, manufacturing and distribution of molecular diagnostic reagents. The Company mainly provides infectious pathogens inspection products, including allergic respiratory pathogens, sexually transmitted diseases pathogens, human papilloma virus (HPV) and other inspection products, drug resistance inspection products, single nucleotide polymorphisms (SNP) inspection products, as well as somatic mutation cancer inspection products. In addition, it is involved in the provision of automatic real-time detection instruments. The Company provides its products under the brand names of Seeplex, Anyplex and Magicplex. The Company distributes its products within domestic market and to overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. A096530 Stock
  4. News Seegene, Inc.
  5. Seegene Develops Diagnostic Reagent for Monkeypox Virus